OmniaBio

Bio & Pharma Medipost, OmniaBio to enhance cooperation for CDMO business

South Korea's stem-cell therapy company Medipost announced on Thursday that its Canadian affiliate OmniaBio made a two-day visit to South Korea on N...

Bio & Pharma Medipost to expand CDMO business with 10 new clean rooms in Korea

Medipost Co, a South Korean biotechnology company, is expanding its cell and gene therapy contract development and manufacturing organization (CDMO)...

Bio & Pharma Medipost acquires Canada’s OmniaBio for CDMO business

Medipost Co., a South Korean biotechnology company, has acquired a 39.6% stake in OmniaBio Inc., a Canada-based cell and gene therapy contract devel...